Description: The monoclonal antibody L26 recognizes human CD20, a two transmembrane spanning protein found on precursor and mature B lymphocytes. Expression is lost upon differentiation to plasma cells. The levels of CD20 are critical in evaluating malignant B lymphocytes including Non-Hodgkin's Lymphoma, and Acute B cell, Chronic Lymphocytic and Hairy-Cell Leukemias. CD20 plays a role in B cell differentiation and activation. The structure of the protein shows a small extracellular loop with the carboxy and amino termini in the cytoplasmic compartment. The L26 antibody recognizes an epitope in the cytoplasmic domain and therefore requires permeabilization of the tissue for staining applications. Unlike many anti-CD20 antibodies that recognize the extracellular domain, the epitope recognized by L26 will not be blocked by therapeutic antibodies to CD20, like Rituximab.
Applications Reported: This L26 antibody has been reported for use in immunohistochemical staining of formalin-fixed paraffin embedded tissue sections.
Applications Tested: This L26 antibody has been tested by immunohistochemistry on formalin-fixed paraffin embedded human tonsils using IHC Antigen Retrieval Solution - Low pH (cat. 00-4955).
eFluor® 660 is a replacement for Alexa Fluor® 647. eFluor® 660 emits at 659 nm and is excited with the red laser (633 nm). Please make sure that your instrument is capable of detecting this fluorochome. This can be used at less than or equal to 20 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Excitation: 633-647 nm; Emission: 668 nm; Laser: Red Laser.
Filtration: 0.2 µm post-manufacturing filtered.
CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation. CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation. CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; B-lymphocyte surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; LEU-16; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; membrane-spanning 4-domains, subfamily A, member 1; MGC3969; MS4A1
Gene Aliases: B1; Bp35; CD20; CVID5; EGK_06167; LEU-16; MS4A1; MS4A2; S7
UniProt ID: (Human) P11836
Molecular Function: receptor